Citation Impact
Citing Papers
A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
2011
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
2015
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
2015
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
2014 StandoutNobel
fastp: an ultra-fast all-in-one FASTQ preprocessor
2018 Standout
Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer
2021 StandoutNobel
ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study
2016
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer
2006
Cancer immunotherapies targeting the PD-1 signaling pathway
2017 StandoutNobel
Breast cancer
2019 Standout
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
2016
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
2008 Standout
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
2016
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients
2015
Breast-cancer detection using blood-based infrared molecular fingerprints
2021 StandoutNobel
The Role of KRAS Mutation Testing in the Management of Patients With Metastatic Colorectal Cancer
2009
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Pancreatic cancer
2004 Standout
A view on drug resistance in cancer
2019 StandoutNature
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
2018
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
2012 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations
2016
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies
2019 Standout
Patient-derived tumour xenografts as models for oncology drug development
2012
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)
2016
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
2015
Lung cancer: current therapies and new targeted treatments
2016 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma
2012
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
2015
Drug repurposing: progress, challenges and recommendations
2018 Standout
Drug development in the era of precision medicine
2017
Deep learning in histopathology: the path to the clinic
2021 Standout
Liquid biopsy
2015
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients
2017
EMT: 2016
2016 Standout
Eicosanoids and cancer
2010 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
2017
Pancreatic Cancer
2010 Standout
Integrated digital error suppression for improved detection of circulating tumor DNA
2016
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
2016
Implications of the tumor immune microenvironment for staging and therapeutics
2017
Targeting immune cells for cancer therapy
2019
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Lysosome-targeting chimaeras for degradation of extracellular proteins
2020 StandoutNatureNobel
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Sensitive Sequencing Method for KRAS Mutation Detection by Pyrosequencing
2005
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Multi-Field-of-View Deep Learning Model Predicts Nonsmall Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images
2019
Pancreatic cancer
2011 Standout
The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System
2017
KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
2009
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
2016
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2017 Standout
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
2017
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
2016
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
2016
Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer
2016
Artificial intelligence in cancer imaging: Clinical challenges and applications
2019 Standout
Current Status of Src Inhibitors in Solid Tumor Malignancies
2011
Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer
2016
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
2010
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
2019
MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts
2011
The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.
2009
Colorectal carcinoma: Pathologic aspects.
2012
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
2018
Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy
2020 StandoutNobel
Works of Jill Walker being referenced
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer
2017
Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer
2009
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
2016
Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
2014
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
2017
Panel Based MALDI-TOF Tumour Profiling Is a Sensitive Method for Detecting Mutations in Clinical Non Small Cell Lung Cancer Tumour
2014
Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients.
2015
Abstract LB-094: A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative
2016
Abstract 2384: A new, highly sensitive IHC test for the detection of HER2 protein in breast cancer (BC) tissue.
2013
K-ras Point Mutation Detection in Lung Cancer: Comparison of Two Approaches to Somatic Mutation Detection Using ARMS Allele-specific Amplification
2000